(Q44117877)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12200697%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

title

Schedule-dependent synergism and antagonism between methotrexate and cytarabine against human leukemia cell lines in vitro (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12200697%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

1 reference

1 reference

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12200697%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

author name string

M Akutsu

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12200697%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

S Tsunoda

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12200697%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

T Izumi

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12200697%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

K Ohmine

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12200697%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

Y Kano

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12200697%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

publication date

1 September 2002

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12200697%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12200697%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

volume

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12200697%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12200697%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

page(s)

1808-1817

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12200697%20AND%20SRC:MED&resulttype=core&format=json

LNH-84 regimen: a multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma

12 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402573

7 January 2021

Treatment of childhood acute lymphoblastic leukemia: results of Dana-Farber Cancer Institute/Children's Hospital Acute Lymphoblastic Leukemia Consortium Protocol 85-01.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402573

7 January 2021

Intraventricular concentration times time (C x T) methotrexate and cytarabine for patients with recurrent meningeal leukemia and lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402573

7 January 2021

Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402573

7 January 2021

AMOPLACE treatment of intermediate-grade and high-grade malignant lymphoma: a Cancer and Leukemia Group B study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402573

7 January 2021

Consolidation therapy with antimetabolite-based therapy in standard-risk acute lymphocytic leukemia of childhood: a Pediatric Oncology Group Study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402573

7 January 2021

Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatme

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402573

7 January 2021

High survival rate in advanced-stage B-cell lymphomas and leukemias without CNS involvement with a short intensive polychemotherapy: results from the French Pediatric Oncology Society of a randomized trial of 216 children

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402573

7 January 2021

Primary non-Hodgkin's lymphoma of the CNS treated with BVAM or CHOD/BVAM chemotherapy before radiotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402573

7 January 2021

Improved survival for children with B-cell acute lymphoblastic leukemia and stage IV small noncleaved-cell lymphoma: a pediatric oncology group study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402573

7 January 2021

Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402573

7 January 2021

Combination chemotherapy: The antagonism of methotrexate and cytosine arabinoside

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402573

7 January 2021

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402573

7 January 2021

Mechanism of synergistic cell killing when methotrexate precedes cytosine arabinoside: study of L1210 and human leukemic cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402573

7 January 2021

Synergistic and antagonistic interactions of methotrexate and 1-beta-D-arabinofuranosylcytosine in hepatoma cells. The modulating effect of purines

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402573

7 January 2021

Synergistic effect of methotrexate and 1-beta-D-arabinofuranosylcytosine on the generation of DNA strand breaks in a human promyelocytic leukemia cell line

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402573

7 January 2021

DRUG SYNERGISM IN ANTINEOPLASTIC CHEMOTHERAPY.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402573

7 January 2021

Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402573

7 January 2021

Establishment of an Epstein-Barr Virus-Determined Nuclear Antigen-Negative Human B-Cell Line From Acute Lymphoblastic Leukemia: Brief Communication2

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402573

7 January 2021

Effects of amsacrine in combination with other anticancer agents in human acute lymphoblastic leukemia cells in culture

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402573

7 January 2021

Effects of CPT-11 in combination with other anti-cancer agents in culture

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402573

7 January 2021

In vitro schedule-dependent interaction between paclitaxel and SN-38 (the active metabolite of irinotecan) in human carcinoma cell lines

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402573

7 January 2021

Phosphorylation of Bcl-2 protein by CDC2 kinase during G2/M phases and its role in cell cycle regulation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402573

7 January 2021

Increase in topoisomerase-II-mediated DNA breaks and cytotoxicity of VP16 in human U937 lymphoma cells pretreated with low doses of methotrexate

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402573

7 January 2021

Preclinical cellular pharmacology of LY231514 (MTA): a comparison with methotrexate, LY309887 and raltitrexed for their effects on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402573

7 January 2021

Biochemical interactions between methotrexate and 1-beta-D-arabinofuranosylcytosine in hematopoietic cells of children: a Pediatric Oncology Group study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402573

7 January 2021

Long-term neuropsychologic sequelae of childhood leukemia: comparison of two CNS prophylactic regimens

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402573

7 January 2021

Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402573

7 January 2021

Cytosine arabinoside cerebrospinal fluid kinetics

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402573

7 January 2021

Variability in the disposition of intraventricular methotrexate: a proposal for rational dosing

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402573

7 January 2021

Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402573

7 January 2021